Medicinova Expands Phase II Ibudilast Study to Include Advanced ALS Patients

Pharmaceutical company MediciNova has started enrolling ALS patients in advanced stages of the disease into its Phase II clinical trial of MN-166, or ibudilast (see Aug 2014 news). The FDA recently approved the company’s amendment to expand the ongoing study in patients not using non-invasive ventilation (NIV) to include 60 advanced ALS patients on NIV support. MN-166 is a small molecule phosphodiesterase 4 and 10 inhibitor and a macrophage migration inhibitory factor inhibitor that suppresses pro-inflammatory cytokines and stimulates expression of neurotrophic factors. The current study is investigating the safety and tolerability of MN-166 when given as an adjunct to riluzole in people in early and late stage ALS.

Click here to read more.

disease-als topic-clinical topic-randd
Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail